{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:49:36Z","timestamp":1768002576109,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.urology.2023.02.003","type":"journal-article","created":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T21:33:39Z","timestamp":1677015219000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study"],"prefix":"10.1016","volume":"175","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4508-6173","authenticated-orcid":false,"given":"Manami","family":"Kinjo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimpei","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuhiro","family":"Tambo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Fukuhara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2023.02.003_bib0001","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/nau.20798","article-title":"An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction","volume":"29","author":"Haylen","year":"2010","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.urology.2023.02.003_bib0002","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1111\/j.1464-410X.2005.05835.x","article-title":"An epidemiological survey of overactive bladder symptoms in Japan","volume":"96","author":"Homma","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2023.02.003_bib0003","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.urology.2009.07.1325","article-title":"Impact on quality of life of urinary incontinence and overactive bladder: a systematic literature review","volume":"75","author":"Bartoli","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.02.003_bib0005","doi-asserted-by":"crossref","first-page":"e2365","DOI":"10.1136\/bmj.e2365","article-title":"The management of overactive bladder syndrome","volume":"344","author":"Marinkovic","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.urology.2023.02.003_bib0006","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/iju.14492","article-title":"Clinical guidelines for female lower urinary tract symptoms (second edition)","volume":"28","author":"Takahashi","year":"2021","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0007","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.urology.2023.02.003_bib0008","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1124\/jpet.106.115840","article-title":"Effect of (R)-2-(2-aminothiazol-4-yl)-4\u2032-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function","volume":"321","author":"Takasu","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.urology.2023.02.003_bib0009","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.eururo.2019.09.024","article-title":"Safety and efficacy of mirabegron: analysis of a large integrated clinical trial database of patients with overactive bladder receiving mirabegron, antimuscarinics, or placebo","volume":"77","author":"Chapple","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0010","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1021\/acs.jmedchem.5b01372","article-title":"Discovery of vibegron: a potent and selective \u03b23 adrenergic receptor agonist for the treatment of overactive bladder","volume":"59","author":"Edmondson","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.urology.2023.02.003_bib0011","doi-asserted-by":"crossref","first-page":"e23171","DOI":"10.1097\/MD.0000000000023171","article-title":"Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder","volume":"100","author":"Su","year":"2021","journal-title":"Med (Baltimore)"},{"key":"10.1016\/j.urology.2023.02.003_bib0012","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2010.06.044","article-title":"Assessment of overactive bladder symptoms: comparison of 3-day bladder diary and the overactive bladder symptoms score","volume":"77","author":"Homma","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.urology.2023.02.003_bib0013","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1442-2042.2008.02177.x","article-title":"Neurogenic bladder society clinical guidelines for overactive bladder","volume":"16","author":"Yamaguchi","year":"2009","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0014","unstructured":"Nagashima K. A computerized number generator through the stratified block randomization. Available at: https:\/\/nshi.jp\/contents\/js\/randblock\/. Accessed January 10, 2020 2017."},{"key":"10.1016\/j.urology.2023.02.003_bib0015","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The measurement committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0016","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.eururo.2013.11.010","article-title":"Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison","volume":"65","author":"Maman","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0017","series-title":"Clinical Guidelines for Overactive Bladder Syndrome","year":"2022"},{"key":"10.1016\/j.urology.2023.02.003_bib0018","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1007\/s12325-021-01902-8","article-title":"Efficacy of vibegron and mirabegron for overactive bladder: a systematic literature review and indirect treatment comparison","volume":"38","author":"Kennelly","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.urology.2023.02.003_bib0019","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/iju.13596","article-title":"Long-term safety and efficacy of the novel \u03b23-adrenoreceptor agonist vibegron in Japanese patients with overactive bladder: a phase III prospective study","volume":"25","author":"Yoshida","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/luts.12417","article-title":"Efficacy of vibegron in patients with overactive bladder: multicenter prospective study of real-world clinical practice in Japan, SCCOP study 19-01","volume":"14","author":"Tachikawa","year":"2022","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.urology.2023.02.003_bib0021","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-2288-5-26","article-title":"The therapeutic effect of clinical trials: understanding placebo response rates in clinical trials\u2014a secondary analysis","volume":"5","author":"Walach","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urology.2023.02.003_bib0022","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.euf.2021.08.011","article-title":"Choosing the most efficacious and safe oral treatment for idiopathic overactive bladder: a systematic review and network meta-analysis","volume":"8","author":"Mostafaei","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2023.02.003_bib0023","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00192-016-3219-x","article-title":"Is mirabegron equally as effective when used as first-or second-line therapy in women with overactive bladder?","volume":"28","author":"Serati","year":"2017","journal-title":"Int Urogynecol J"},{"key":"10.1016\/j.urology.2023.02.003_bib0024","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.euf.2020.06.015","article-title":"Treatment of non-neurogenic lower urinary tract symptoms\u2014a review of key publications from 2018 onward","volume":"7","author":"Abreu-Mendes","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urology.2023.02.003_bib0025","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2017.12.022","article-title":"Vibegron, a novel potent and selective \u03b23-adrenoreceptor agonist, for the treatment of patients with overactive bladder: a randomized, double-blind, placebo-controlled phase 3 study","volume":"73","author":"Yoshida","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2023.02.003_bib0026","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1053\/j.gastro.2007.05.009","article-title":"Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system","volume":"133","author":"Cellek","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.urology.2023.02.003_bib0027","first-page":"131","article-title":"Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS)","volume":"20","author":"Kelleher","year":"2008","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.urology.2023.02.003_bib0028","unstructured":"Japanese Ministry of Health, Labour and Welfare. Comprehensive survey of living conditions. Available at: https:\/\/www.mhlw.go.jp\/toukei\/saikin\/hw\/k-tyosa\/k-tyosa13\/dl\/16.pdf, Accessed January 10, 2020 2013."},{"key":"10.1016\/j.urology.2023.02.003_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2022.100674","article-title":"Selectivity and maximum response of vibegron and mirabegron for \u03b23-adrenergic receptors","volume":"96","author":"Brucker","year":"2022","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.1016\/j.urology.2023.02.003_bib0030","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/nau.24732","article-title":"Cardiovascular safety of vibegron, a new \u03b23-adrenoceptor agonist, in older patients with overactive bladder: post-hoc analysis of a randomized, placebo-controlled, double-blind comparative phase 3 study","volume":"40","author":"Yoshida","year":"2021","journal-title":"Neurourol Urodyn"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429523001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:12:17Z","timestamp":1758769937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429523001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":30,"alternative-id":["S0090429523001498"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2023.02.003","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Mirabegron and Vibegron in Women With Treatment-Naive Overactive Bladder: A Randomized Controlled Study","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2023.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}